XENE

Xenon Pharmaceuticals Inc

Mar 23 • 04:00PM ET

54.42

-0.52 -0.95 %

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP ONC ARGX ARWR AKRO EDIT ACAD AGEN KURA ARDX

| Held by: IWM IWO IBB VTWO SPDW SBIO NUSC VTWG ESML VT

Index	RUT	P/E	-	EPS (ttm)	-4.36	Insider Own	3.52%	Shs Outstand	83.19M	Perf Week	-0.44%
Market Cap	4.53B	Forward P/E	-	EPS next Y	-4.66	Insider Trans	-11.67%	Shs Float	80.26M	Perf Month	28.87%
Enterprise Value	3.99B	PEG	-	EPS next Q	-1.18	Inst Own	99.08%	Short Float	6.89%	Perf Quarter	25.88%
Income	-345.91M	P/S	603.63	EPS this Y	-10.02%	Inst Trans	0.10%	Short Ratio	4.04	Perf Half Y	47.28%
Sales	7.50M	P/B	7.48	EPS next Y	2.93%	ROA	-33.77%	Short Interest	5.53M	Perf YTD	21.42%
Book/sh	7.27	P/C	8.25	EPS next 5Y	12.26%	ROE	-51.76%	52W High	63.95 -14.90%	Perf Year	53.99%
Cash/sh	6.60	P/FCF	-	EPS past 3/5Y	-28.36% -40.02%	ROIC	-58.81%	52W Low	26.74 103.52%	Perf 3Y	60.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-7.36% -25.26%	Gross Margin	66.09%	Volatility	3.28% 5.07%	Perf 5Y	210.79%
Dividend TTM	-	EV/Sales	531.50	EPS Y/Y TTM	-44.99%	Oper. Margin	-4974.27%	ATR (14)	2.85	Perf 10Y	726.42%
Dividend Ex-Date	-	Quick Ratio	13.42	Sales Y/Y TTM	-	Profit Margin	-4612.13%	RSI (14)	60.84	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	13.42	EPS Q/Q	-56.77%	SMA20	7.14%	Beta	0.81	Target Price	79.14
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	20.01%	Rel Volume	1.15	Prev Close	54.94
Employees	370	LT Debt/Eq	0.01	Earnings	Feb 26 AMC	SMA200	36.69%	Avg Volume	1.37M	Price	54.42
IPO	Nov 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.94% -	Trades		Volume	1,558,097	Change	-0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$60
Sep-03-25	Resumed	Wells Fargo	Overweight	$48
May-07-25	Initiated	Chardan Capital Markets	Buy	$55
Feb-11-25	Initiated	Deutsche Bank	Buy	$67
Oct-10-24	Resumed	Raymond James	Outperform	$50
Oct-01-24	Initiated	H.C. Wainwright	Buy	$53
Jan-04-24	Initiated	Citigroup	Buy	$62
Dec-08-23	Initiated	Robert W. Baird	Outperform	$63
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight	$58
Dec-14-22	Initiated	Goldman	Buy	$60
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight	$50
Oct-19-22	Initiated	Raymond James	Outperform	$52
Aug-29-22	Initiated	BofA Securities	Buy	$45
Jul-21-22	Initiated	JP Morgan	Overweight	$55
Oct-28-21	Initiated	RBC Capital Mkts	Outperform	$43
Oct-02-20	Initiated	SVB Leerink	Outperform	$22
Jul-21-20	Initiated	Needham	Buy	$22
Jun-01-20	Resumed	Jefferies	Buy	$23

Show Previous Ratings

Mar-12-26 04:01PM	Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-11-26 06:00AM	Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 (TipRanks)
Mar-10-26 10:39PM	Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering (GlobeNewswire)
11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
07:00PM	Loading…
Mar-09-26 07:00PM	50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today (24/7 Wall St.) +49.64%
04:25PM	Xenon Smashes Its Previous Record High On 'Unprecedented' Results. Is A Buyout Next? (Investor's Business Daily)
04:01PM	Xenon Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
01:50PM	Analysts tout market potential of Xenons epilepsy drug on Phase III win (Clinical Trials Arena)
11:47AM	What's Going On With Biohaven Stock On Monday? (Benzinga)
09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
07:00AM	Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) (GlobeNewswire)
Mar-08-26 02:00PM	Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 (GlobeNewswire)
Mar-04-26 01:36PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
Feb-27-26 09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
05:04PM	Loading…
Feb-26-26 05:04PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 01:08PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
Jan-16-26 04:05PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 08:30AM	Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:30AM	Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.07%
Dec-05-25 09:00AM	Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire)
Dec-04-25 05:20PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? (Zacks)
08:30AM	Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 (GlobeNewswire)
Nov-25-25 08:30AM	Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire)
Nov-06-25 08:30AM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-04-25 09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
12:01AM	Loading…
12:01AM	Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Nov-03-25 04:32PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Third Quarter 2025 Financial Results & Business Update (GlobeNewswire)
Oct-27-25 08:30AM	Xenon to Report Q3 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-16-25 08:30AM	Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer (GlobeNewswire)
Oct-07-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-25 04:01PM	Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Aug-29-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +5.51%
03:06AM	Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Aug-11-25 06:03PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Second Quarter 2025 Financial Results & Business Update (GlobeNewswire)
Aug-04-25 08:01AM	Xenon to Report Q2 2025 Financial Results on August 11, 2025 (GlobeNewswire) +8.72%
Aug-01-25 04:55PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:30AM	Compass Pathways Appoints Justin Gover to Board of Directors (Business Wire)
Jul-02-25 03:20AM	RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug (Insider Monkey)
Jun-27-25 04:01PM	Xenon Joins the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-26-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 08:30AM	Xenon Announces Appointment of Darren Cline as Chief Commercial Officer (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-25 04:01PM	Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-25 04:01PM	Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
08:18AM	Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday (Insider Monkey)
May-13-25 12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks) -17.43%
03:09AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-12-25 04:10PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:24AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-05-25 04:01PM	Xenon to Report Q1 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.29%
09:55AM	Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? (Zacks)
May-02-25 04:42PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-04-25 04:23PM	Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (Seeking Alpha)
08:30AM	Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 (GlobeNewswire)
Mar-12-25 04:01PM	Xenon to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-28-25 02:36AM	Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Feb-27-25 04:18PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-26-25 07:28AM	What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 04:01PM	Xenon to Present at the 45th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-20-25 04:01PM	Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-13-25 08:30AM	Xenon Outlines Key Corporate Milestone Opportunities for 2025 (GlobeNewswire)
Jan-07-25 08:30AM	Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 11:30AM	Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? (Zacks) -8.19%
Dec-06-24 04:01PM	Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 (GlobeNewswire)
Nov-22-24 09:30AM	JPMorgan Selects These 2 Stocks as Must-Haves for 2025 (TipRanks)
Nov-13-24 04:01PM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
02:17AM	Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Nov-12-24 04:07PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q3 2024 Financial Results and Business Update (GlobeNewswire)
Nov-11-24 07:06AM	Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2024 Result (GuruFocus.com)
Nov-05-24 04:01PM	Xenon to Report Q3 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-09-24 05:54PM	Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-02-24 04:28PM	Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference (GlobeNewswire)
Sep-09-24 08:30AM	Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress (GlobeNewswire)
Sep-05-24 01:12AM	Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-21-24 10:46AM	Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe (Zacks)
Aug-12-24 08:30AM	Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer (GlobeNewswire)
Aug-09-24 10:19AM	Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down (Zacks)
Aug-08-24 09:59PM	XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:26PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q2 2024 Financial Results and Business Update (GlobeNewswire)
Aug-01-24 04:01PM	Xenon to Report Q2 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-27-24 03:54PM	Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? (Insider Monkey)
Jun-05-24 04:01PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Mar 13 '26	Sale	55.23	1,410	77,867	7,069	Mar 13 08:16 PM
DiFabio Andrea	Chief Legal Officer	Mar 13 '26	Sale	55.23	1,342	74,112	7,301	Mar 13 08:16 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 13 '26	Sale	55.23	7,308	403,584	19,923	Mar 13 08:16 PM
CHRISTOPHER JOHN KENNEY	Officer	Mar 13 '26	Proposed Sale	55.22	1,410	77,867		Mar 13 07:51 PM
ANDREA DIFABIO	Officer	Mar 13 '26	Proposed Sale	55.23	1,342	74,112		Mar 13 07:50 PM
IAN MORTIMER	Officer	Mar 13 '26	Proposed Sale	55.22	7,308	403,583		Mar 13 07:49 PM
KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Mar 10 '26	Sale	60.11	2,771	166,559	4,729	Mar 11 07:21 PM
DiFabio Andrea	Chief Legal Officer	Mar 10 '26	Sale	60.11	2,607	156,702	4,893	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 09 '26	Option Exercise	6.74	270,000	1,819,850	111,000	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 09 '26	Sale	60.33	270,000	16,289,142	6,000	Mar 11 07:20 PM
MORTIMER IAN	PRESIDENT & CEO	Mar 10 '26	Sale	60.11	11,269	677,357	14,731	Mar 11 07:20 PM
ANDREA DIFABIO	Officer	Mar 10 '26	Proposed Sale	60.11	2,607	156,702		Mar 10 09:01 PM
CHRISTOPHER JOHN KENNEY	Officer	Mar 10 '26	Proposed Sale	60.11	2,771	166,559		Mar 10 08:58 PM
IAN MORTIMER	Officer	Mar 10 '26	Proposed Sale	60.11	11,269	677,357		Mar 10 08:57 PM
IAN MORTIMER	Officer	Mar 09 '26	Proposed Sale	60.33	270,000	16,289,196		Mar 09 04:46 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 02 '26	Option Exercise	7.49	40,000	299,600	46,000	Jan 02 06:49 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 02 '26	Sale	44.43	40,000	1,777,093	6,000	Jan 02 06:49 PM
IAN MORTIMER	Officer	Jan 02 '26	Proposed Sale	44.43	40,000	1,777,166		Jan 02 06:47 PM
MORTIMER IAN	PRESIDENT & CEO	Dec 05 '25	Sale	45.03	14,375	647,306	16,830	Dec 09 07:40 PM
MORTIMER IAN	PRESIDENT & CEO	Dec 08 '25	Sale	45.73	10,830	495,207	6,000	Dec 09 07:40 PM
IAN MORTIMER	Officer	Dec 08 '25	Proposed Sale	45.73	10,830	495,248		Dec 08 05:10 PM
IAN MORTIMER	Officer	Dec 05 '25	Proposed Sale	45.03	14,375	647,360		Dec 05 05:54 PM
MORTIMER IAN	PRESIDENT & CEO	Nov 28 '25	Sale	45.01	97	4,366	31,205	Dec 03 08:20 PM
IAN MORTIMER	Officer	Nov 28 '25	Proposed Sale	45.01	97	4,366		Dec 01 07:36 PM
MORTIMER IAN	PRESIDENT, CEO & INTERIM CFO	Oct 01 '25	Option Exercise	7.69	25,000	192,250	56,302	Oct 01 07:17 PM
MORTIMER IAN	PRESIDENT, CEO & INTERIM CFO	Oct 01 '25	Sale	40.16	25,000	1,004,000	31,302	Oct 01 07:17 PM
IAN MORTIMER	Officer	Oct 01 '25	Proposed Sale	40.16	25,000	1,004,117		Oct 01 07:13 PM
SHERRY AULIN	Former officer	Sep 19 '25	Proposed Sale	37.08	2,548	94,490		Sep 19 09:10 PM
GANNON STEVEN	Director	Jun 05 '25	Sale	30.48	3	91	7,141	Jun 06 05:58 PM
GANNON STEVEN	Director	May 14 '25	Option Exercise	12.57	5,144	64,660	7,144	May 16 05:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XENE

Xenon Pharmaceuticals Inc

Upgrade your FINVIZ experience